Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
patients with metastatic colorectal cancer who were initially RAS wild and failed at least 2
lines of chemotherapy will be enrolled. Anti-EGFR must have been given in 1st line. Those who
remain RAS-wild upon retesting will receive rechallenge with panitumumab and chemotherapy